ラウリン酸
Based on 7 publication(s) in Google Scholar
Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.93%
- CAS 番号: 143-07-7
- 分子式: C12H24O2
- 分子量:200.32
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Human Endogenous Metabolite Compound Library
HY-L030
-
Drug Repurposing Compound Library
HY-L035
-
Lipid Compound Library
HY-L043
-
Antibacterial Compound Library
HY-L049
-
Medicine Food Homology Compound Library
HY-L055
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Animal-Sourced Natural Product Library
HY-L157
-
FDA-Approved Traditional Chinese Medicine Active Compound Library
HY-L163
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Fatty Acids Compound Library
HY-L182
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Tibetan Medicine Compound Library
HY-L191
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
RO5 Drug-like Natural Product Library
HY-L200
-
Flavor Compound Library
HY-L202
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mouse Metabolite Compound Library
HY-L217
-
Cosmetic Ingredient Compound Library
HY-L221
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Lipid Metabolite Compound Library
HY-L228
-
Mongolian Medicine Compound Library
HY-L238
-
Chinese Baijiu Compound Library
HY-L241
-
Flavors and Fragrances Compound Library
HY-L242
-
Natural Product Diversity Scaffold Library
HY-L245
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Environmental Pollutant Compound Library
HY-L247
-
Mass Spectrometry Natural Product Library
HY-L262
-
Drug Fragment Library
HY-L904
MedChemExpress（MCE）の使用を引用している文献 Lauric acid
More- Nature. 2025 Jul;643(8070):192-200. [Abstract]
- Food Sci Hum Wellness. 2026 Mar 3.
- Nutrients. 2025 Feb 25;17(5):794. [Abstract]
- Int Immunopharmacol. 2026 May 1:176:116468. [Abstract]
- Mol Neurobiol. 2024 Nov;61(11):9302-9319. [Abstract]
- Biochem Biophys Res Commun. 2026 Mar 12:804:153358. [Abstract]
- Res Sq. 2025 Nov 18.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Flow Cytometry
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
3.49 μM
Compound: 18
|
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay
|
[PMID: 31721581] |
| CHO | EC50 |
8.87 μM
Compound: 18
|
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m
Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m
|
[PMID: 31721581] |
Lauric acid (0.06-125 μg/ml, 24-72 h) has much stronger antimicrobial activity in P. acnes, S.aureus, and S. epidermidis[1].
Lauric acid (5-50 μM, 24 h) increases glucose uptake and decreases GLUT-1 expression and cellular H2O2 production in insulin-resistant macrophages[2].
Lauric acid (5-50 μM, 24 h) enhances mitochondrial content and mitochondrial biogenesis in the insulin-resistant macrophages[2].
Lauric acid (5-50 μM, 24 h) promotes the gene expressions (PPAR-γ, TFAM and PGC-1α) in THP-1 macrophages[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Lauric acid (1-10 mg/kg, i.v., once time) reduces blood pressure and heart rate in WKY and SHR rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 143-07-7
-
性状 Solid
-
分子量 200.32
-
分子式 C12H24O2
-
Color White to off-white
-
SMILES
CCCCCCCCCCCC(O)=O
-
別名
Lauric acid
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jul;643(8070):192-200. PMID: 39695227 -
-
Nutrients
Medium-Chain Fatty Acids Selectively Sensitize Cancer Cells to Ferroptosis by Inducing CD36 and ACSL4. [Abstract]2025 Feb 25;17(5):794. PMID: 40077664
Lauric acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2025 Feb 25;17(5):794. [Abstract]
U937 human leukemia cells were treated with Lauric acid (LA-m), RSL3 or their combination in the absence or presence of ferroptosis inhibitor Lip-1 for 24 h, and their viability was assayed using CCK8.
Lauric acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2025 Feb 25;17(5):794. [Abstract]
RINm5F rat insulinoma cells were exposed to Lauric acid (LA-m) and RSL3 alone or their combination in the absence or presence of ferroptosis inhibitor Lip-1 for 24 h, and the changes of cell viability were measured through crystal violet staining.
Lauric acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2025 Feb 25;17(5):794. [Abstract]
U937 human leukemia cells were treated with Lauric acid (LA-m), LA-l or their combination for 24 h, and cell viability was assessed by CCK8.
Lauric acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2025 Feb 25;17(5):794. [Abstract]
RINm5F rat insulinoma cells were treated with Lauric acid (LA-m), LA-l or their combination for 24 h, and cell viability was determined by crystal violet staining.
Lauric acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2025 Feb 25;17(5):794. [Abstract]
After the treatment, the levels of intracellular LPO were quantified using flow cytometry after staining with Liperfluo in U937 human leukemia cells. "+" means: combination of Lauric acid and LA-l.
Lauric acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2025 Feb 25;17(5):794. [Abstract]
CD36 and ACSL4 protein levels in A549 lung cancer cells with treatment with Lauric acid for 12 h.
-
Int Immunopharmacol
Minimolide F alleviates inflammatory diseases by specifically targeting STING and blocking IRF3 recruitment. [Abstract]2026 May 1:176:116468. PMID: 41819671 -
Mol Neurobiol
Brain Immune Cell Infiltration and Serum Metabolomic Characteristics Reveal that Lauric Acid Promotes Immune Cell Infiltration in Brain and Streptococcus suis Meningitis in Mice. [Abstract]2024 Nov;61(11):9302-9319. PMID: 38625620 -
Biochem Biophys Res Commun
2026 Mar 12:804:153358. PMID: 41619507 -
溶剤 & 溶解度
DMSO : 100 mg/mL (499.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
0.1 M NaOH : 10 mg/mL (49.92 mM; ultrasonic and warming and adjust pH to 11 with NaOH and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (10.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (270 KB)
-
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Nakatsuji T, et al. Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol. 2009 Oct;129(10):2480-8. [Content Brief]
[2]. Tham YY, et al. Lauric acid alleviates insulin resistance by improving mitochondrial biogenesis in THP-1 macrophages. Mol Biol Rep. 2020 Dec;47(12):9595-9607. [Content Brief]
[3]. Alves NF, et al. Acute Treatment with Lauric Acid Reduces Blood Pressure and Oxidative Stress in Spontaneously Hypertensive Rats. Basic Clin Pharmacol Toxicol. 2017 Apr;120(4):348-353. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| 0.1 M NaOH / DMSO | 1 mM | 4.9920 mL | 24.9601 mL | 49.9201 mL | 124.8003 mL |
| 5 mM | 0.9984 mL | 4.9920 mL | 9.9840 mL | 24.9601 mL | |
| 10 mM | 0.4992 mL | 2.4960 mL | 4.9920 mL | 12.4800 mL | |
| 15 mM | 0.3328 mL | 1.6640 mL | 3.3280 mL | 8.3200 mL | |
| 20 mM | 0.2496 mL | 1.2480 mL | 2.4960 mL | 6.2400 mL | |
| 25 mM | 0.1997 mL | 0.9984 mL | 1.9968 mL | 4.9920 mL | |
| 30 mM | 0.1664 mL | 0.8320 mL | 1.6640 mL | 4.1600 mL | |
| 40 mM | 0.1248 mL | 0.6240 mL | 1.2480 mL | 3.1200 mL | |
| DMSO | 50 mM | 0.0998 mL | 0.4992 mL | 0.9984 mL | 2.4960 mL |
| 60 mM | 0.0832 mL | 0.4160 mL | 0.8320 mL | 2.0800 mL | |
| 80 mM | 0.0624 mL | 0.3120 mL | 0.6240 mL | 1.5600 mL | |
| 100 mM | 0.0499 mL | 0.2496 mL | 0.4992 mL | 1.2480 mL |
Powered by Bioz